Corbus Pharmaceuticals Receives Fast Track from FDA for Cervical Cancer Treatment

Corbus Pharmaceuticals received a fast-track designation from the Food and Drug Administration for its treatment of relapsed or refractory metastatic cervical cancer. The Norwood, Mass., oncology company on Tuesday said the treatment, CRB-701, is being tested for safety and efficacy in a Phase 1 clinical trial in patients with advanced solid tumors known to be associated with high Nectin-4 expression. CRB-701 targets Nectin-4, which is a cell adhesion protein that is over-expressed in many types of human cancers. Corbus said it expects to report the first data from the study during the first quarter of 2025. Read more >>